The functional roles of metabotropic glutamate receptor (mGluR) 1 in integrative brain functions were investigated using a potent and selective mGluR1 allosteric antagonist, FTIDC [4-[1-(2-fluoropyridine-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide], in comparison with the mGluR5 allosteric antagonist and the mGluR2/3 orthosteric agonist in rodents. FTIDC reduced maternal separationinduced ultrasonic vocalization and stress-induced hyperthermia without affecting behaviors in the elevated plus maze. An mGluR5 antagonist, 2-methyl-6-(phenylethynyl)-pyridine (MPEP), and an mGluR2/3 agonist, LY379268 [(1R, 4R,5S,6R)-4-amino-2-oxabicyclo[3.1.0]hexane-4,6-dicarboxylic acid], showed anxiolytic activities in these models, suggesting involvement of postsynaptic mGluR1 in stress-related responses comparable with mGluR5 and mGluR2/3. Analgesic effects of FTIDC were seen in the formalin test but not in the tail immersion test. FTIDC selectively blocked methamphetamineinduced hyperlocomotion and disruption of prepulse inhibition, whereas MPEP and LY379268 did not alter those behaviors, suggesting that pharmacological blockade of mGluR1 could result in antipsychotic-like effects. FTIDC did not elicit catalepsy or impair motor functions at 10 times higher dose than doses showing antipsychotic-like action. In conclusion, blockade of mGluR1 showed antipsychotic-like effects without impairing motor functions, whereas blockade of mGluR5 and activation of mGluR2/3 did not display such activities.
lular calcium. Group II (mGluR2 and mGluR3) and group III (mGluR4, mGluR6, mGluR7, and mGluR8) mGluRs are negatively coupled via G i to adenylyl cyclase, resulting in the inhibition of cyclic adenosine monophosphate production and protein kinase A activity.
The mGluRs are expressed on neuronal and glial cells, with each receptor subtype exhibiting distinct spatial and temporal expression profiles in the brain (Shigemoto et al., 1992) , with the exception of mGluR6 existing in the retina (Nakajima et al., 1993) . In neurons, group I mGluRs are mainly localized in somatodendritic domains and postsynaptically regulate neuronal excitability and synaptic transmission via several intracellular second messenger systems, whereas group II and III mGluRs are predominantly localized in axonal domains and axon terminals to presynaptically regulate neurotransmitter release (Shigemoto et al., 1992) . In fact, activation of mGluR2/3 has been demonstrated using in vivo microdialysis techniques to reduce the release of various neurotransmitters , including glutamate (Battaglia et al., 1997) .
One of the most interesting and earliest breakthroughs in the development of agents targeting mGluRs was the identification of highly selective agonists for group II mGluRs, such as LY354740 and LY379268. These compounds have demonstrated anxiolytic effects in rodents (Helton et al., 1998; Kłodziń ska et al., 1999) and humans (Grillon et al., 2003) . In addition, activation of mGluR2/3 may lead to anticonvulsive (Kłodziń ska et al., 2000) , antinociceptive (Simmons et al., 2002) , and antipsychotic (Cartmell et al., 1999 effects.
Because these results with activation of mGluR2/3 suggest that control of excessive excitation in glutamatergic neurotransmission is one of the underlying mechanisms, some of the pharmacological effects of mGluR2/3 activation may be mimicked by modulating postsynaptic glutamate receptors, including both ionotropic glutamate receptors (iGluRs) and mGluRs. N-methyl-D-aspartate (NMDA) antagonists show anxiolytic and antinociceptive effects in animal models (Fundytus, 2001; Cortese and Phan, 2005) and generally cause psychotic behaviors in animals and humans (Javitt, 2004) . Non-NMDA antagonists produce antinociception in pain models; however, effects on anxiety remain controversial (Cortese and Phan, 2005) . These findings suggested that some effects of mGluR2/3 agonists by reducing glutamatergic neurotransmission are not fully dependent upon iGluRs pathways. Blockade of mGluR5 with its allosteric antagonists ethynyl]pyridine has demonstrated amelioration of anxiety (Tatarczyń -ska et al., 2001; Busse et al., 2004) and nociception (Zhu et al., 2004; Varty et al., 2005) . Blockade of mGluR5 and activation of mGluR2/3 may share similar outcomes to some extent. On the other hand, roles of mGluR1 in the pharmacological effects of mGluR2/3 agonists have not been well studied.
Demonstration of pharmacological effects by blockade of mGluR1 has been hampered by the lack of appropriate antagonists until the recent development of allosteric antagonists, including JNJ16259685, BAY 36-7620, YM-230888, and EMQMCM (De Vry et al., 2001; Lavreysen et al., 2004; Sevostianova and Danysz, 2006; Kohara et al., 2007) . Of these, only JNJ16259685 has been demonstrated to be CNSpermeable and act as a selective mGluR1 allosteric antagonist, showing full receptor occupancy in the brain at and above 0.16 mg/kg (Lavreysen et al., 2004b) . JNJ16259685 demonstrated anxiolytic effects in the Vogel conflict test, reduction of spontaneous motor activities, and impairment of spatial acquisition in the Morris water maze (Steckler et al., 2005a,b) . However, the (patho)physiological roles of mGluR1 in other brain functions in which activation of mGluR2/3 altered have not been tested with JNJ16259685.
We have recently identified FTIDC as a potent and selective mGluR1 allosteric antagonist (Suzuki et al., 2007) . FT-IDC blocked DHPG-induced face-washing behaviors at doses of 10 and 30 mg/kg in mice, indicating that these doses of FTIDC inhibited mGluR1-mediated brain functions in vivo (Suzuki et al., 2007) and that FTIDC was a useful tool for exploring the pharmacological roles of mGluR1 in CNS. The purpose of this study is to evaluate the extent of effects of FTIDC in animal models of anxiety, nociception, and psychosis. Effects of FTIDC were compared with those of the mGluR5 antagonist and the mGluR2/3 agonist.
Materials and Methods

Animals.
All experiments were performed using adult male CD1 (ICR) mice (Japan SLC, Shizuoka, Japan), C57BL/6J mice (Clea Japan, Tokyo, Japan), and Sprague-Dawley rats (Charles River Laboratories Japan, Kanagawa, Japan). Animals were housed in an air-conditioned room with a 12:12 light/dark cycle (lights off at 7:00 PM) and allowed ad libitum access to food (CE-2; Clea Japan) and tap water. At least 6 days were allowed for acclimatization to the facility before starting experiments. All experiments were approved by our Institutional Animal Care and Use Committee.
Compounds and Administration Procedures. The structure for FTIDC was disclosed in our previous article (Suzuki et al., 2007) . FTIDC was used in all experiments as the free base. FTIDC was suspended into 0.5% methylcellulose for intraperitoneal administration. We detected 0.8 Ϯ 0.4 M in plasma and 0.4 Ϯ 0.2 nmol/g in the brain 30 min after administration of 30 mg/kg FTIDC. These concentrations in plasma and brain were 26-and 13-fold higher concentration than the concentration required to completely suppress agonist-induced increases in intracellular Ca 2ϩ (0.03 M), respectively (Suzuki et al., 2007) . Thus, the behavioral studies are conducted between 30 and 60 min after administration. Specific time was noted in each behavioral assay. Dosing volume was 10 and 1 ml/kg for mice and rats, respectively. MPEP and LY379268 (Tocris Cookson Inc., Ellisville, MO) were administered intraperitoneally in a suspension of 0.5% methylcellulose. Methamphetamine (MAP) was purchased from Dainippon Sumitomo Pharma (Osaka, Japan) and dissolved in physiological saline for subcutaneous administration. The following drugs were used as positive control drugs to demonstrate sensitivity of methods in appropriate animal models. Haloperidol (Serenece; Dainippon Sumitomo Pharma) was diluted by distilled water for subcutaneous administration. Morphine (Takeda Pharmaceutical Co., Ltd., Osaka, Japan) was dissolved in physiological saline for subcutaneous injection. Diazepam (Wako Pure Chemicals, Osaka, Japan) was administered intraperitoneal in a suspension of 0.5% methylcellulose.
Elevated Plus Maze in Mice. The elevated plus maze was made from gray polyvinyl chloride and consisted of two open arms (length, 30 cm ϫ width, 5 cm; surrounded by a 0.3-cm rim) and two enclosed arms (length, 30 cm ϫ width, 5 cm; with 15-cm-high walls), which extended from a central platform (5 ϫ 5 cm). The maze was elevated 70 cm above the floor and was illuminated by a dim light (60 lux) at the end of each open arm. Experiments were monitored through a charge-coupled device camera (Watec, Yamagata, Japan) placed 1.5 m above the maze and then recorded and analyzed automatically using TARGET software (Neuroscience, Tokyo, Japan). A C57BL/6J mouse was brought to the vestibule of the experimental room at least 
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30 min before the start of the experiment. At 30 min after intraperitoneal injection of the test compound, mice (n ϭ 10 -26/group) were placed in the center of the maze facing an open arm. During the following 5-min period, time spent on and the numbers of entries onto each arm were recorded. An arm entry was defined when all four paws entered the arm. The maze was wiped using distilled water after each trial. Experiments were performed between 9:00 AM and 5:00 PM.
Measurement of Maternal Separation-Induced Ultrasonic Vocalization in Rat Pups. On the day of the study, rat pups (postnatal day 10) were moved with their mother to the experimental room and left undisturbed for at least 60 min. Pups (n ϭ 4 -12/group) received an intraperitoneal injection of test drugs and then returned to the mother. After 30 min, each pup was placed in a stainless steel chamber (size: , 10.5 ϫ height, 16 cm) on a Cool Plate (NCP-2215; Nisshin Rika, Tokyo, Japan), which maintained temperature of the chamber at 24°C in a sound-proof room (AT-81; Rion, Tokyo, Japan). The number of ultrasonic vocalizations was measured for 5 min. Individual calls made by each offspring during this period were collected by microphone, amplified by a dedicated preamplifier (NH-05A; Rion) and a main amplifier (NH-04A; Rion) with a filter (multifunction filter 3611; NF Corporation, Kanagawa, Japan; settings: high pass, 1.5 kHz). Analog signals were then converted to digital signals by an A/D converter (CH-3150; Exacq Technologies, Indianapolis, IN) and stored in a personal computer. Transferred digital data were automatically counted using recording software developed by our group (DasyLab 7.0; MeasX, Mönchengladbach, Germany). The threshold value was set at a signal amplitude of 0.1 V to exclude noise. Each pup was immediately returned to its mother in the home cage after measurement. Behavioral changes under drug treatment were observed during the experiment, and body surface temperature of each pup was also monitored using an infrared thermometer (Thermo-Hunter PT3S; Optex, Shiga, Japan) immediately before the recording sessions.
Stress-Induced Hyperthermia in Mice. The effects of FTIDC on stress-induced hyperthermia (SIH) were examined using the modified classic SIH paradigm described by Olivier et al. (2003) . On the experiment day, all ICR mice used in the study were transferred from group housing to individual housing before the test and were allowed to acclimatize to the experimental environment for at least 60 min. The first measurement captured basal core temperature (T 1 ) and then 10 min later, a second measurement (T 2 ) captured temperature under stress. The difference between the first and second temperatures (⌬T ϭ T 2 Ϫ T 1 ) was defined as SIH. Rectal temperature was measured with a lubricated thermistor probe (Physitemp Instruments, Inc., Clifton, NJ) inserted into the rectum of each subject. Test compounds were administered to mice (n ϭ 7-8/group) by intraperitoneal route 60 min before first measurement.
Formalin Test in Mice. ICR mice (n ϭ 6 -10/group) were individually placed in a clear plastic chamber (13 ϫ 10 ϫ 15.5 cm). Animals were habituated to the chamber for more than 60 min before the experimental sessions, and then 20 l of formalin (2%) was injected subcutaneously into the foot pad of the mouse hind paw using a 30-gauge needle. After injection, mice were immediately returned to the chamber, and formalin-induced behaviors were recorded for a period of 40 min. All tested substances were injected 30 min before formalin administration. The duration of licking and biting of the injected paw was measured manually. For analysis of antinociceptive effects of drugs, the period from immediately to 10 min after formalin injection was defined as the first phase, and the period from 15 to 25 min after formalin injection was defined as the second phase.
Spontaneous Locomotor Activity and MAP-Induced Hyperlocomotion in Mice. Locomotor activity of ICR mice was measured by an activity-monitoring system (NS-AS01; Neuroscience) in a test cage using previously reported methods (Narita et al., 2002) . In brief, the activity monitor was composed of the infrared ray sensor placed over each test cage (length, 22.5 cm ϫ width, 33.8 cm ϫ height, 14.0 cm), a signal amplification circuit, and a control circuit. Motor activity was collected every 1 min, and data were stored and analyzed with a computer-associated analyzing system (DAS System-24A; Neuroscience). Animals (n ϭ 6 -17/group) were administered test compounds and then immediately placed into the test cage. Spontaneous locomotor activity was then measured for 1 h. In the drug interaction study, either mGluR1 antagonist or haloperidol was administered 30 min before MAP was injected at 2 mg/kg s.c. Immediately after MAP injection, the mouse was placed into the test cage, and locomotor activity was measured for 1 h.
Measurement of Prepulse Inhibition in Rats. Sprague-Dawley rats were used to measure prepulse inhibition (PPI) in the Startle Response System (SR-Lab; San Diego Instruments, San Diego, CA). The whole apparatus was housed in a ventilated chamber (length, 39 cm ϫ width, 38 cm ϫ height, 58 cm). Presentation of acoustic stimuli was controlled by SR-Lab software and interface that digitized, rectified, and recorded responses from the accelerometer in a personal computer. Mean startle amplitude was determined by averaging 100 1-ms readings taken at the pulse stimulus onset. On the day of PPI testing, rats (n ϭ 8 -13/group) were placed into the startle apparatus. After a period of 5 min, during which rats were exposed to background noise (60 dB), the session began with rats being exposed to different auditory stimuli. The session began with 15 of each of the following six trial types: 1) startle stimulus (120 dB, 40 ms); 2 to 4) startle stimulus preceded by 100 ms by prepulses at 3, 6, and 12 dB above background noise (60 dB) and lasting 20 ms; 5) prepulse stimulus (72 dB, 20 ms); and 6) no stimulus. These six trial types were interspersed across 15 consecutive blocks. Intertrial interval was pseudorandomly varied between 15 and 30 s, and sessions lasted approximately 35 min. Data collected in the first five blocks were discarded due to large variance of startle responses, and data from the last 10 blocks were analyzed. Haloperidol was administered 15 min before the beginning of the session, and other drugs were administered 30 min before the session. In the case of drug interaction studies, MAP at 3 mg/kg was subcutaneously injected 10 min before the session.
Catalepsy Assay in Rats. Catalepsy was determined by placing the front paws of the animal over a rod raised approximately 10 cm above the floor. The duration for which the animal remained in this forced position was measured with a "cut-off" of 60 s. The measurement procedure was repeated three times, and the longest duration holding onto a raised rod with the front paws was taken for subsequent analysis. Test compounds were administered into rats (n ϭ 5-15/group) 60 min before this study.
Rotorod Test in Mice. Effects of test compounds on motor coordination were evaluated using the Rotorod apparatus (model 7650; Ugo Basile, Comerio, Italy) in the ICR mouse. Mice were trained twice on the apparatus on the day of testing. In the first training session, mice were trained to walk on the rotating rod (8 revolutions/ min) for 5 min. Approximately 1 h after the first training session, mice that walked for at least 3 min without falling off were selected in the second training session. Rotorod performance before drug administration in selected mice was given as 120 s. In the test session, the duration that mice (n ϭ 9 -10/group) walked on the rotating rod was measured 30, 60, and 120 min after administration of test compounds.
Grip Strength Test in Mice. Forelimb grip strength was determined using a strain gauge (GPM-100; Melquest, Toyama, Japan). The forepaws of ICR mice were allowed to grab a horizontal bar mounted on the gauge, and the tail was slowly pulled back by an experimenter. Tension was recorded from the gauge at the time the mouse released the forepaws from the horizontal bar. Measurements were repeated three times, and maximum tension from the three measurements was used in analyses. Test compounds were administered into mice (n ϭ 5-8/group), and grip strength was measured at before and 30, 60, and 120 min after dosing.
Data Analyses and Statistics. Data analyses were performed using Prism software (version 4.00; GraphPad Software Inc., San 
Results
Elevated Plus Maze in Mice. LY379268 at 1 and 3 mg/kg did not alter behaviors in the elevated plus maze (Fig. 1, A and E). FTIDC at both 10 and 30 mg/kg i.p. had no effect on time spent on each arm but decreased the number of entries into closed arms at 30 mg/kg (Fig. 1, B and F) . Conversely, MPEP increased both time spent on and number of entries into open arms, with significant changes at 3 and 30 mg/kg. In addition, MPEP decreased time spent in closed arms with increases in number of entries into closed arms at 30 mg/kg (Fig. 1, C and G) . Diazepam significantly increased both time in and entry into open arms in a dose-dependent manner (Fig. 1, D and H) .
Ultrasonic Vocalization in the Rat. LY379268, FTIDC, MPEP, and diazepam significantly decreased vocalizations in dose-dependent manners (Fig. 2, A-D ). LY379268 at 1 mg/kg elicited motor suppression without changes in body temperature, but body temperature was significantly decreased at 3 mg/kg (p Ͻ 0.05; vehicle, 36.6 Ϯ 0.2°C; LY379268, 35.2 Ϯ 0.5°C). FTIDC did not alter either motor function or body temperature. MPEP at 30 mg/kg significantly decreased body temperature (p Ͻ 0.05; vehicle, 34.6 Ϯ 0.4°C; MPEP, 33.4 Ϯ 0.2°C) without motor suppression. Sedation and hypothermia (p Ͻ 0.01; vehicle, 36.1 Ϯ 0.3°C; diazepam, 34.2 Ϯ 0.3°C) was seen in animals treated with diazepam at 1 mg/kg, whereas no changes in motor activity or body temperature were noted at 0.1 and 0.3 mg/kg. SIH in Mice. LY379268 significantly decreased SIH responses at 1 and 3 mg/kg without any effects on basal core temperature ( Fig. 3A ; Table 1 ). FTIDC suppressed SIH response at 30 mg/kg without any changes in basal body temperature ( Fig. 3B; Table 1 ). MPEP attenuated SIH response at 30 mg/kg, with significant decreases in basal body temperature ( Fig. 3C; Table 1 ). Diazepam at 1 mg/kg significantly decreased SIH response (Fig. 3D ) without affecting basal body temperature (Table 1) .
Formalin Test in Mice. Intrafoot pad injection of formalin caused biphasic licking responses. LY379268 did not show significant effects on licking behavior in either the first or second phases (Fig. 4A) . FTIDC significantly inhibited licking or biting behavior elicited by formalin in a dose-dependent manner in both phases (Fig. 4B) . MPEP significantly reduced formalin-induced licking at 30 mg/kg in both phases (Fig. 4C) . Morphine significantly decreased licking latencies in a dose-dependent manner from 1 mg/kg in the first phase, and 10 mg/kg morphine was required to block licking behavior in the second phase (Fig. 4D) .
Spontaneous Locomotor Activity and MAP-Induced Hyperlocomotion in Mice. LY379268 significantly inhibited hyperlocomotion induced by MAP at 3 mg/kg, with obvious reduction of spontaneous locomotor activity from 0.3 mg/kg (Fig. 5, A and E) . FTIDC significantly decreased MAPinduced hyperlocomotion in a dose-dependent manner from 1 to 30 mg/kg (Fig. 5F ) without affecting basal spontaneous locomotor activity (Fig. 5B) . MPEP significantly attenuated MAP-induced hyperlocomotion only at a dose of 30 mg/kg, which caused hypolocomotion by itself (Fig. 5, C and G) . Haloperidol significantly antagonized hyperlocomotion induced by MAP in a dose-dependent manner from 0.1 to 1 mg/kg (Fig. 5H) , whereas haloperidol suppressed spontaneous locomotor activity at 0.3 mg/kg (Fig. 5D) .
PPI in Rats. MAP (3 mg/kg s.c.) significantly disrupted PPI in rats at 6-or 12-dB prepulse intensity (Fig. 6, A-D) . LY379268 did not affect either impaired PPI (Fig. 6A ) or spontaneous PPI (Table 2) . MAP-induced deficits of PPI were partially reversed by FTIDC at 10 to 30 mg/kg (Fig. 6B ). FTIDC decreased spontaneous PPI at these doses (Table 2) . In contrast, MPEP exaggerated MAP-induced disruption of PPI at a dose of 30 mg/kg (Fig. 6C ) without affecting spontaneous PPI (Table 2) . Haloperidol reversed MAP-induced deficits in PPI at doses of 0.03 and 0.3 mg/kg (Fig. 6D ) without altering spontaneous PPI (Table 2) . Catalepsy Assay in Rats. FTIDC at up to 100 mg/kg did not cause any catalepsy, whereas haloperidol elicited catalepsy in a dose-dependent manner, and four of 10 rats treated with 0.3 mg/kg showed a cut-off time of 60 s (Table 3) .
Rotorod Test in Mice. FTIDC at doses of 3 to 30 mg/kg had negligible effects on motor coordination in the Rotorod test (Fig. 7A) . Conversely, haloperidol significantly impaired motor coordination at doses of 0.3 and 1 mg/kg (Fig. 7B) .
Grip Strength Test in Mice. FTIDC at doses of 10 and 30 mg/kg did not affect muscle tone of mice in the grip test ( 
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Discussion
Because mGluR2/3 agonists have shown anxiolytic, antinociceptive, and antipsychotic effects, modulation of glutamatergic neurotransmission has been considered as a potential therapeutic target for these CNS disorders (Kłodziń ska et al., 1999 (Kłodziń ska et al., , 2000 Simmons et al., 2002; Grillon et al., 2003) . Alteration of glutamatergic neurotransmission could be achieved not only by presynaptic regulation of glutamate release with mGluR2/3 but also by postsynaptic modulation with iGluRs, mGluR1, and/or mGluR5. The studies with NMDA, non-NMDA, and mGluR5 antagonists suggested that pharmacological effects of mGluR2/3 agonists via reduction of glutamatergic neurotransmission cannot be fully explained by postsynaptic blockade of iGluRs and mGluR5 (Fundytus, 2001; Javitt, 2004; Zhu et al., 2004; Cortese and Phan, 2005; Varty et al., 2005) . In contrast to studying the pharmacological effects of iGluRs and mGluR5 antagonists, studies to explore pharmacological effects of mGluR1 antagonists have been limited. JNJ16259685 demonstrated full mGluR1 occupancy in rat brain at and above 0.16 mg/kg (Lavreysen et al., 2004b) and showed anxiolytic effects, reduction of spontaneous locomotor activities, and impairment of spatial acquisition in the Morris water maze at higher doses (Steckler et al., 2005a,b) . Other mGluR1 allosteric antagonists demonstrated some pharmacological effects but might be insufficient to conclude that pharmacological effects were due to in vivo antagonism against mGluR1-mediated functions. Recently, FTIDC was identified as a potent and selective mGluR1 allosteric antagonist that reduces DHPG-induced face-washing behavior at 10 and 30 mg/kg (Suzuki et al., 2007) . Because DHPG-induced face-washing behaviors are due to activation of mGluR1 (Barton and Shannon, 2005; Hikichi et al., 2008) , we used these doses of FTIDC to elucidate pharmacological roles of mGluR1 in vivo and compared with those of the mGluR2/3 agonist and the mGluR5 antagonist.
New findings with FTIDC were that blockade of mGluR1 showed antipsychotic-like effects in various animal models. MAP-induced hyperlocomotion was dose-dependently attenuated by FTIDC, whereas LY379268 or MPEP did not alter MAP-induced hyperlocomotion. Because the dose range of FTIDC effective in MAP-induced hyperlocomotion was similar to that inhibiting DHPG-induced face-washing behavior (Suzuki et al., 2007) , antagonistic activities of FTIDC against MAP-induced hyperlocomotion were probably due to selective blockade of mGluR1. LY379268 dose-dependently suppressed spontaneous locomotion in mice, whereas MPEP only inhibited locomotion at the highest dose. FTIDC did not alter spontaneous locomotion. These results indicate that maintenance of glutamate neurotransmission via iGluRs is important to basal locomotor activity. We observed that mGluR1-deficient mice treated with MAP displayed smaller increases in horizontal movement than wild type (see supplemental data). Because amphetamines are known to increase locomotion and glutamate release in the ventral tegmental area and nucleus accumbens (Xue et al., 1996; Wolf and Xue, 1999) , it seems likely that increased glutamate release participated in amphetamine-induced hyperlocomotion. Selective modulation of dopaminergic neurons via mGluR1 might be explained by the finding that DHPG-induced increases in intracellular calcium concentration of dopaminergic neurons are blocked by CPCCOEt, but not by MPEP (Tozzi et al., 2001 ).
When we investigated effects of FTIDC on MAP-induced disruption of PPI, FTIDC partially reversed MAP-induced disruption of PPI in the same dose range as in the MAPinduced hyperlocomotion test. A limited study examining the antipsychotic activities of BAY 36-7620 at 10 mg/kg reported efficacy in suppression of stereotypic behaviors induced by MK-801, but not by amphetamine or apomorphine (De Vry et al., 2001) and PPI disruption by MK-801, phencyclidine, and apomorphine (Spooren et al., 2003) . However, in ex vivo occupancy studies, BAY 36-7620 at 10 mg/kg only occupied about 30% of cerebellar and thalamic mGluR1 (Lavreysen et al., 2004a) , suggesting that BAY 36-7620 at doses in these reports might be insufficient to fully block mGluR1. Although JNJ16259685 demonstrated nearly full mGluR1 occupancy at 0.16 mg/kg, JNJ16259685 has not been tested on these antipsychotic activities. The present findings are the first to demonstrate antipsychotic-like effects of mGluR1 allosteric antagonist on psychotic animal models. MPEP exaggerated MAP-induced PPI disruption without affecting spontaneous PPI, being in the same line as findings that selective mGluR5-positive modulator antagonizes amphetamine-induced PPI deficits (Kinney et al., 2005) . LY379268 did not affect either spontaneous PPI or MAP-induced PPI disruption. Although LY354740 has been reported to attenuate the disruptive effects of phencyclidine on working memory, stereotypy, locomotion, and cortical glutamate efflux (Moghaddam and Adams, 1998) , LY354740 and LY379268 did not reverse phencyclidine-, ketamine-, or amphetamine-induced disruption of PPI (Galici et al., 2005; Imre et al., 2006) , arguing against antipsychotic activities of mGluR2/3-selective agonists. Because pharmacological effects of the mGluR2/3 agonist could be due to the summation of mGluR1 and mGluR5 blockade, mGluR2/3 agonist might not change MAP-induced disruption of PPI as a whole. For further support of this new possible therapeutic role of mGluR1, FTIDC should be examined in other psychotic animal models depending on nondopaminergic mechanisms. FTIDC did not impair motor coordination, decrease muscle tone, or display catalepsy, sug- gesting that blockade of mGluR1 could not elicit extrapyramidal motor side effects, unlike marketed antipsychotics. We tested anxiolytic potential of mGluR ligands in three different studies. CD1 mice were used in the SIH test. We used rat pups in the USV test because we could not measure stable USVs due to low vocalization signal strength compared with those in rat pups. In the elevated plus maze test, we used C57BL/6J mice because C57BL/6J mice were more sensitive to diazepam than CD1 mice. FTIDC significantly decreased both USV in rat pups and SIH in mice. However, FTIDC did not alter behaviors in the elevated plus maze. These results may be due to different levels and/or modalities MPEP MPEP C (9) (7) (6) (9) (7)
veh 1 of anxiety or stress in these models. JNJ16259685 demonstrated anxiolytic activity in the Vogel conflict model, but not in the elevated zero maze (Steckler et al., 2005a Taking these results together, blockade of mGluR1 would exert specific anxiolytic effects rather than general anxiolytic actions shown by diazepam, and reduction of glutamate transmission via both mGluR1 and mGluR5 might be responsible for at least some anxiolytic effects of the mGluR2/3 agonist.
Antinociceptive effects of mGluR1 antagonists have been tested in both acute and chronic pain models; however, there was no analgesic effect in acute pain models (Spooren et al., 2003) . We tested the antinociceptive effects of mGluR ligands in the mouse formalin test. FTIDC inhibited formalin-induced nociceptive behavior. Conversely, FTIDC did not inhibit acute thermal pain in the same dosage (see supplemental data), suggesting that mGluR1 could be involved in the sensitization process elicited by chemical stimuli, rather than acute pain responses to thermal stimulation. Our results are supported by studies with EMQMCM (Sevostianova and Danysz, 2006) . Antinociceptive effects of MPEP have been well studied (Zhu et al., 2004; Varty et al., 2005) and are consistent with our results. Although antinociceptive responses of LY379268 were reported in the rat formalin test (Simmons et al., 2002) , activation of mGluR2/3 did not show analgesic effects comparable with those with FTIDC or MPEP in the present study with mice, which might be due to a lack of presynaptic regulation of glutamate transmission by mGluR2/3 in the pain pathway. This could be supported by immunocytochemical findings that mGluR2/3 is distributed mainly in lamina IIi and virtually absent in laminae I and IIo in the rat dorsal horn, where the primary afferent neurons from dorsal root ganglia terminate and mGluR1-and mGluR5-positive cells have been detected (Jia et al., 1999) .
In summary, the present study clarified the contribution of postsynaptic mGluR1 and mGluR5 to pharmacological effects of the mGluR2/3 agonist, which is considered to regulate release of glutamate. Anxiolytic effects of mGluR2/3 may mainly relate to the reduction of synaptic transmission via mGluR5. However, mGluR1 may also be involved in anxiolytic effects of mGluR2/3 when the state of anxiety is high. Analgesic effects were pronounced by blockade of mGluR1 or mGluR5, rather than action of mGluR2/3, probably due to existence of mGluR1 and mGluR5, but not mGluR2/3, in the superficial layer of the spinal dorsal horn. Finally, reductions in neural activity via mGluR1 may participate in antipsy- 
